Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03192462 · ClinicalTrials.gov registry record · Phase 1
TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT03192462 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 37 participants.
The verdict
NCT03192462, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
Status - CLOSED TO PATIENT ENROLLMENT (CNPE) Patients who have pancreatic cancer that has come back or has not gone away after treatment, including the standard treatment for this disease or patients who are not eligible for or have elected not to receive standard of care chemotherapy, and patients who will have surgery after treatment for pancreatic cancer are eligible for this study. This is a research study using special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy. The proteins that are targeted in this study are called tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They do not show, or they show up in low quantities, on normal human cells. In this study, five common TAAs will be targeted. They are called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX2. On a different study, patients have been treated and so far this treatment has shown to be safe. Investigators now want to try this treatment in patients with pancreatic cancer. These TAA-specific cytotoxic T lymphocytes (TAA-CTLs) are an investigational product not approved by the Food and Drug Administration. \*Arm A and Arm B are closed to new patient enrollment.\*
Interventions
- BIOLOGICAL multiTAA specific T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03192462
The ClinicalTrials.gov registry entry for NCT03192462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which multiTAA specific T cells is the first listed.
NCT03192462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03192462 about?
NCT03192462 is a clinical study titled "TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer". Status - CLOSED TO PATIENT ENROLLMENT (CNPE) Patients who have pancreatic cancer that has come back or has not gone away after treatment, including the standard treatment for this disease or patients who are not eligible for or have elected not to receive standard of care chemotherapy, and patients...
What is the current status of trial NCT03192462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2018-01-18. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT03192462?
The interventions under investigation include: multiTAA specific T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03192462?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.